ロード中...
Which MCI patients should be included in prodromal Alzheimer’s disease clinical trials?
BACKGROUND: Prodromal Alzheimer’s disease (AD) clinical trials enroll patients with Mild Cognitive Impairment (MCI) meeting biomarker criteria, but specific enrollment criteria vary among trials. METHODS: We used data from AD Neuroimaging Initiative (ADNI) MCI participants to assess AD biomarker eli...
保存先:
| 出版年: | Alzheimer Dis Assoc Disord |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6538436/ https://ncbi.nlm.nih.gov/pubmed/30958413 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/WAD.0000000000000303 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|